Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,900

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

3,900 results for “parkinsonism”

Learn how ShareScore rates datasets ↗
zenodo32/100

Parkinson disease validation algorithms

<p>The primary objective of this study was to validate two algorithms for the identification of persons with PD using clinical diagnosis as the reference standard on an Italian sample of people with PD.&nbsp;</p> <p>Two algorithms (index tests) applied to health administrative databases (hospital discharge, drug prescriptions, exemptions for medical costs) were validated against clinical diagnosis of PD by an expert neurologist (reference standard) in a cohort of consecutive outpatients.</p> <p>The two algorithms showed high accuracy for identifying patients with PD: one with greater sensitivity 94.2% (95% CI 88.4 &ndash; 97.6) and the other with greater specificity 98.1% (95% CI 97.7 &ndash; 98.5).</p>

opencc-by-4.0May 2023View details →
zenodo32/100

Single-nucleus RNA-sequencing reveals oligodendrocytes and their progenitors as vulnerable cell types in prefrontal cortex and anterior cingulate of brains with Parkinson's disease

<p>Several prior studies have proposed the involvement of various brain regions and cell types in Parkinson&#39;s disease (PD) pathology. Here, we performed snRNA-seq on the prefrontal cortex and anterior cingulate regions from post-mortem control and PD brain tissue. We found a dramatic association of oligodendrocytes and oligodendrocyte precursor cells with PD-linked risk loci and reported several dysregulated genes and pathways, including regulation of tau-protein kinase activity, regulation of inclusion body assembly and protein processing involved in protein targeting to mitochondria.</p>

opencc-by-4.0May 2023View details →
zenodo32/100

Intensive training programme improves handwriting in a community cohort of people with Parkinson's disease

<p><strong>Background</strong>: People with Parkinson&rsquo;s disease (PwP) often report problems with their handwriting before they receive a formal diagnosis. Many PwP suffer from deteriorating handwriting throughout their illness, which has detrimental effects on many aspects of their quality of life. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p> <p><strong>Aims:</strong> To assess a 6-week online training programme aimed at improving handwriting of PwP.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>Methods</strong>: Handwriting samples from a community-based cohort of PwP (n=48) were analysed using Systematic Detection of Writing Problems (SOS-PD) by two independent raters, before and after a 6-week remotely-monitored Physiotherapy-led training programme. Inter-rater variability on multiple measures of handwriting quality was analysed. The handwriting data was analysed using pre/post design in the same individuals. Multiple aspects of the handwriting samples were assessed, including writing fluency, transitions between letters, regularity in letter size, word spacing, and straightness of lines.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>Results</strong>: Analysis of inter-rater reliability showed high agreement for total handwriting scores, letter size, as well as speed and legibility scores, whereas there were mixed levels of inter-rater reliability for other handwriting measures. Overall handwriting quality (p=0.001) and legibility (p=0.009) significantly improved, while letter size (p=0.012), fluency (p=0.001), regularity of letter size (p=0.009) and straightness of lines (p=0.036) were also enhanced.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>Conclusions</strong>: The results of this study show that this 6-week intensive remotely-monitored Physiotherapy-led handwriting programme, improved handwriting in PwP. This is the first of its kind study using this tool remotely and it demonstrated that the SOS-PD is reliable for measuring handwriting in PwP.</p> <p><strong>Background</strong>: People with Parkinson&rsquo;s disease (PwP) often report problems with their handwriting before they receive a formal diagnosis. Many PwP suffer from deteriorating handwriting throughout their illness, which has detrimental effects on many aspects of their quality of life. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p> <p><strong>Aims:</strong> To assess a 6-week online training programme aimed at improving handwriting of PwP.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>Methods</strong>: Handwriting samples from a community-based cohort of PwP (n=48) were analysed using Systematic Detection of Writing Problems (SOS-PD) by two independent raters, before and after a 6-week remotely-monitored Physiotherapy-led training programme. Inter-rater variability on multiple measures of handwriting quality was analysed. The handwriting data was analysed using pre/post design in the same individuals. Multiple aspects of the handwriting samples were assessed, including writing fluency, transitions between letters, regularity in letter size, word spacing, and straightness of lines.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>Results</strong>: Analysis of inter-rater reliability showed high agreement for total handwriting scores, letter size, as well as speed and legibility scores, whereas there were mixed levels of inter-rater reliability for other handwriting measures. Overall handwriting quality (p=0.001) and legibility (p=0.009) significantly improved, while letter size (p=0.012), fluency (p=0.001), regularity of letter size (p=0.009) and straightness of lines (p=0.036) were also enhanced.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>Conclusions</strong>: The results of this study show that this 6-week intensive remotely-monitored Physiotherapy-led handwriting programme, improved handwriting in PwP. This is the first of its kind study using this tool remotely and it demonstrated that the SOS-PD is reliable for measuring handwriting in PwP.</p>

opencc-byMay 2023View details →
zenodo32/100

Generalizable electroencephalographic classification of Parkinson's disease using deep learning

<p>This is the data originally accessed from&nbsp;http://predict.cs.unm.edu/downloads.php&nbsp;</p> <p>Here, we provide the pre-processed data from our manuscript to allow for the easy replication of our experiments.&nbsp;</p> <p>Here is the repo associated with our paper: https://github.com/diamandis-lab/CNN_EEG_PD&nbsp;</p>

opencc-by-4.0Sep 2023View details →
zenodo32/100

Omics data integration suggests a potential idiopathic Parkinson's disease signature

<p>Dataset linked to the manuscript under revision: <strong>Omics data integration suggests a potential idiopathic Parkinson's disease signature.</strong><i><strong> </strong>Complete manuscript information can be found here: https:/doi.org/</i>10.17881/v8jg-pw83</p>

opencc-by-4.0Oct 2023View details →
ClinicalTrials.gov32/100

rTMS to Improve Cognition in Parkinson's

ClinicalTrials.gov study NCT03836950. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Split-belt Treadmill Training for Freezing of Gait in Parkinson's Disease

ClinicalTrials.gov study NCT05511597. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Effect of WB-EMS on Parkinson's Disease

ClinicalTrials.gov study NCT04878679. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Efficacy of Nano-PSO in Parkinson's Disease.

ClinicalTrials.gov study NCT05142085. IPD Sharing: NO. Countries: 1. Publications: 12.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Exercise Intervention and Dexterity in Parkinson

ClinicalTrials.gov study NCT01749917. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease

ClinicalTrials.gov study NCT00180037. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

ClinicalTrials.gov study NCT04870372. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease

ClinicalTrials.gov study NCT01155492. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Riluzole to Treat Parkinson's Disease

ClinicalTrials.gov study NCT00013624. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Galantamine Executive Function in Parkinson's Disease

ClinicalTrials.gov study NCT00211588. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease

ClinicalTrials.gov study NCT01114321. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Effects of Deep Brain Stimulation in Parkinson's Disease

ClinicalTrials.gov study NCT00855621. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

EMD 128130 for the Treatment of Parkinson's Disease

ClinicalTrials.gov study NCT00009048. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

The Acute Effect of Cervical Mobilization in Parkinson's Disease

ClinicalTrials.gov study NCT04524143. IPD Sharing: NO. Countries: 1. Publications: 8.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

ClinicalTrials.gov study NCT03790670. IPD Sharing: NO. Countries: 1. Publications: 5.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record